| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 1995;26:670-675.)
© 1995 American Heart Association, Inc.
Articles |
Effects of Hypertension and Dyslipidemia on the Decline in Renal Function
From the Department of Medicine, Helsinki (Finland) University Central Hospital.
Correspondence to Matti Mänttäri, MD, Department of Medicine, Helsinki University Central Hospital, Haartmaninkatu 4, SF 00290 Helsinki, Finland.
Abstract Experimental evidence suggests that in addition to hypertension, serum lipids might also accelerate the decline in renal function. We tested this hypothesis in 2702 dyslipidemic middle-aged men without renal disease participating in the Helsinki Heart Study, a coronary primary prevention trial. The decline in renal function was estimated from linear regression slopes based on reciprocals of 10 serum creatinine determinations over the study period. Renal function deteriorated 3% on average during the 5-year study, and hypertension accelerated this change. Subjects with an elevated ratio of low- to high-density lipoprotein cholesterol (>4.4) had a 20% faster decline than those with a ratio less than 3.2. Both the contribution of the lipoprotein ratio and the protective effect of high-density lipoprotein cholesterol alone remained significant in multiple regression analyses. In the study of joint effects the contribution of lipids was confined to subjects with simultaneous elevation of blood pressure and lipids. The results suggest that in addition to hypertension, blood lipids also modify the decline in renal function.
Key Words: cholesterol • lipoproteins, HDL cholesterol • creatinine • kidney
This article has been cited by other articles:
 |
|
 |
|
  C. M. O'Seaghdha, V. Perkovic, T. H. Lam, S. McGinn, F. Barzi, D. F. Gu, A. Cass, I. Suh, P. Muntner, G. G. Giles, et al. Blood Pressure Is a Major Risk Factor for Renal Death: An Analysis of 560 352 Participants From the Asia-Pacific Region Hypertension, September 1, 2009; 54(3): 509 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. H. de Boer, B. C. Astor, H. Kramer, W. Palmas, S. L. Seliger, M. G. Shlipak, D. S. Siscovick, M. Y. Tsai, and B. Kestenbaum Lipoprotein Abnormalities Associated with Mild Impairment of Kidney Function in the Multi-Ethnic Study of Atherosclerosis Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 125 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. M. Campese and J. Park HMG-CoA Reductase Inhibitors and Renal Function Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1100 - 1103. [Full Text] [PDF]
|
|
|
|
 |
|
 V. G. Athyros, D. P. Mikhailidis, E. N. Liberopoulos, A. I. Kakafika, A. Karagiannis, A. A. Papageorgiou, K. Tziomalos, E. S. Ganotakis, and M. Elisaf Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: A subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study Nephrol. Dial. Transplant., January 1, 2007; 22(1): 118 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. I. Parikh, S.-J. Hwang, M. G. Larson, J. B. Meigs, D. Levy, and C. S. Fox Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch Intern Med, September 25, 2006; 166(17): 1884 - 1891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Tovar and D. B. Schering Management of Dyslipidemia in Special Populations Journal of Pharmacy Practice, April 1, 2006; 19(2): 63 - 78. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Boes, D. Fliser, E. Ritz, P. Konig, K. Lhotta, J. F.E. Mann, G. A. Muller, U. Neyer, W. Riegel, P. Riegler, et al. Apolipoprotein A-IV Predicts Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease Study J. Am. Soc. Nephrol., February 1, 2006; 17(2): 528 - 536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kurella, J. C. Lo, and G. M. Chertow Metabolic Syndrome and the Risk for Chronic Kidney Disease among Nondiabetic Adults J. Am. Soc. Nephrol., July 1, 2005; 16(7): 2134 - 2140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Chade, A. Lerman, and L. O. Lerman Kidney in Early Atherosclerosis Hypertension, June 1, 2005; 45(6): 1042 - 1049. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Stuveling, S. J. L. Bakker, H. L. Hillege, P. E. de Jong, R. O. B. Gans, and D. de Zeeuw Biochemical risk markers: a novel area for better prediction of renal risk? Nephrol. Dial. Transplant., March 1, 2005; 20(3): 497 - 508. [Full Text] [PDF]
|
|
|
|
|
|
V. M. Campese, M. K. Nadim, and M. Epstein Are 3-Hydroxy-3-Methylglutaryl-CoA Reductase Inhibitors Renoprotective? J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S11 - S17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Afzali, A. A. Haydar, K. Vinen, and D. J.A. Goldsmith From Finland to Fatland: Beneficial Effects of Statins for Patients with Chronic Kidney Disease J. Am. Soc. Nephrol., August 1, 2004; 15(8): 2161 - 2168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V G Athyros, D P Mikhailidis, A A Papageorgiou, A N Symeonidis, A N Pehlivanidis, V I Bouloukos, and M Elisaf The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study J. Clin. Pathol., July 1, 2004; 57(7): 728 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Afzali, A. A. Haydar, K. Vinen, and D. J. A. Goldsmith Beneficial effects of statins on the kidney: the evidence moves from mouse to man Nephrol. Dial. Transplant., May 1, 2004; 19(5): 1032 - 1036. [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Fox, M. G. Larson, E. P. Leip, B. Culleton, P. W. F. Wilson, and D. Levy Predictors of New-Onset Kidney Disease in a Community-Based Population JAMA, February 18, 2004; 291(7): 844 - 850. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Schaeffner, T. Kurth, G. C. Curhan, R. J. Glynn, K. M. Rexrode, C. Baigent, J. E. Buring, and J. M. Gaziano Cholesterol and the Risk of Renal Dysfunction in Apparently Healthy Men J. Am. Soc. Nephrol., August 1, 2003; 14(8): 2084 - 2091. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. B. Appel, J. Radhakrishnan, M. M. Avram, R. A. DeFronzo, F. Escobar-Jimenez, M.M. Campos, E. Burgess, D. A. Hille, T. Z. Dickson, S. Shahinfar, et al. Analysis of Metabolic Parameters as Predictors of Risk in the RENAAL Study Diabetes Care, May 1, 2003; 26(5): 1402 - 1407. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.L. Hillege, W.H. van Gilst, D.J. van Veldhuisen, G. Navis, D.E. Grobbee, P.A. de Graeff, and D. de Zeeuw Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial Eur. Heart J., March 1, 2003; 24(5): 412 - 420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. de Jong, H. L. Hillege, S. J. Pinto-Sietsma, and D. de Zeeuw Screening for microalbuminuria in the general population: a tool to detect subjects at risk for progressive renal failure in an early phase? Nephrol. Dial. Transplant., January 1, 2003; 18(1): 10 - 13. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ribstein, G. Du Cailar, and A. Zanchetti Cardiac and renal damage in the elderly hypertensive Journal of Renin-Angiotensin-Aldosterone System, March 1, 2002; 3(1_suppl): S16 - S24. [PDF]
|
|
|
|
|
|
J. Syrjanen, J. Mustonen, and A. Pasternack Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy Nephrol. Dial. Transplant., January 1, 2000; 15(1): 34 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. A. Massy, T. N. Khoa, B. Lacour, B. Descamps-Latscha, N. K. Man, and P. Jungers Dyslipidaemia and the progression of renal disease in chronic renal failure patients Nephrol. Dial. Transplant., October 1, 1999; 14(10): 2392 - 2406. [Abstract] [Full Text] [PDF]
|
|